Table 5. Clinical trials of various vascular grafts. This table aims to be representative rather than comprehensive.
| Intervention/treatment | Number of patients | Condition/disease | Years | Trial ID/phase | Testing status |
|---|---|---|---|---|---|
| Device: Synthetic vascular grafts | 207 | Peripheral arterial occlusive disease | 2010-2013 | NCT01113892/NA | Completed |
| Device: HAVG graft implantation | 40 | End-stage renal disease Kidney failure, chronic |
2012-2016 | NCT01744418/NA | Active, not recruiting |
| Device: FUSION Vascular Graft | 117 | Peripheral arterial occlusive disease (PAOD) | 2009-2013 | NCT01601496/NA | Terminated |
| Device: POSS-PCU vascular graft | 30 | Renal insufficiency | 2021-2025 | NCT02301312/NA | Not yet recruiting |
| Combination Product: Tissue Engineered Vascular Grafts | 4 | Single ventricle cardiac anomaly | 2009-2017 | NCT01034007/Phase 1 | Completed |
| Device: ProEndoTecc Vascular Graft | 33 | Peripheral arterial disease Peripheral vascular disease |
2010-2012 | NCT01095237/NA | Terminated |
| Device: ASC coated ePTFE vascular graft Device: Propaten graft |
60 | Lower limb ischemia | 2011-2022 | NCT01305863/NA | Active, not recruiting |
| Biological: natural human collagen arteriovenous graft for haemodialysis access | 10 | End stage renal disease | 2021-2022 | NCT04905511/Phase 1 | Recruiting |
| Device: POSS-PCU vascular graft | 30 | Renal insufficiency | 2021-2025 | NCT02301312/NA | Not yet recruiting |
| Procedure: Revascularisation using a BIOPROTEC graft | 45 | Peripheral artery disease | 2018-2023 | NCT04018846/NA | Recruiting |
| Device: Expanded polytetrafluoroethylene graft Device: Bovine carotid artery graft |
10 | End stage renal disease Haemolysis Arteriovenous graft | 2015-2018 | NCT03300024/NA | Terminated (Funding ended) |
| Device: Expedial vascular access graft | 172 | End stage renal disease | 2004-2006 | NCT00131872/Phase 2 | Terminated |
| Device: Covera vascular covered stent | 100 | Arteriovenous fistula | 2020-2023 | NCT04261686/NA | Enrolling by invitation |
| Device: Endovascular revascularisation of peripheral arteries | 150 | Vascular diseases, peripheral | 2021-2022 | NCT04765566/NA | Active, not recruiting |
| Device: InnAVasc arteriovenous graft surgical implant | 26 | Kidney failure, chronicRenal dialysis | 2019-2021 | NCT03645681/NA | Active, not recruiting |
| Procedure: blood sampling procedurethe vascular prosthesis manufactured by electrospinning | 120 | Arterial occlusive disease | 2014-2015 | NCT02255188/NA | Completed |
| Procedure: revascularisation Device: Propaten® Device: Crude PTFE |
228 | Ischemia lesions | 2018-2023 | NCT03430076/NA | Recruiting |
| Device: Paclitaxel-eluting graft | 20 | Haemodialysis access failure | 2018-2023 | NCT04285073/NA | Recruiting |
| Device: GORE PROPATEN vascular graft Procedure: Disadvantaged autologous vein graft |
31 | Peripheral arterial occlusive disease | 2007-2010 | NCT00617279/Phase 4 | Terminated (study terminated due to low enrolment) |
| Device: EvoCit Device: EvoHep |
38 | Kidney diseases Haemodialysis complication End stage renal disease | 2018-2019 | NCT03887468/ | Completed |
| Combination product: Tissue engineered vascular grafts | 24 | Cardiovascular diseases | 2020-2025 | NCT04467671/Phase 2 | Recruiting |
Note: The information is obtained from clinicaltrials.gov. NA: not available.